All of the following are medications used to slow progression of mild to moderate Alzheimer's disease EXCEPT:

Prepare for the American Board of Professional Psychology (ABPP) Exam with flashcards and multiple-choice questions. Each question includes insights and explanations to help you excel. Get ready for your certification journey!

Multiple Choice

All of the following are medications used to slow progression of mild to moderate Alzheimer's disease EXCEPT:

Slowing progression in mild to moderate Alzheimer's disease is mainly achieved with cholinesterase inhibitors, which boost acetylcholine activity in the brain and help maintain cognitive function and daily abilities. Donepezil, rivastigmine, and galantamine are all cholinesterase inhibitors with evidence supporting their use in mild to moderate stages. Memantine works differently, by blocking NMDA receptors to reduce glutamatergic excitotoxicity, and is approved for moderate to severe Alzheimer's disease. Its benefit in the mild to moderate stage is not established, so it isn’t the agent used to slow progression at that stage. That’s why memantine is the exception.

Slowing progression in mild to moderate Alzheimer's disease is mainly achieved with cholinesterase inhibitors, which boost acetylcholine activity in the brain and help maintain cognitive function and daily abilities. Donepezil, rivastigmine, and galantamine are all cholinesterase inhibitors with evidence supporting their use in mild to moderate stages.

Memantine works differently, by blocking NMDA receptors to reduce glutamatergic excitotoxicity, and is approved for moderate to severe Alzheimer's disease. Its benefit in the mild to moderate stage is not established, so it isn’t the agent used to slow progression at that stage. That’s why memantine is the exception.

More practice questions